ACRV stock forecast, quote, news & analysis
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform... Show more
Why Acrivon Therapeutics (ACRV) Stock Is Down -15.5% in the Last 30 Days
Key Takeaways
- Acrivon Therapeutics (ACRV) shares declined roughly 15.5% over the last 30 days, falling from a closing price near $2.06 to about $1.74.
- The pullback largely unwound a sharp mid-August rally, with the stock still trading above its early-August level near $1.56.
- Acrivon is a clinical-stage precision oncology company advancing its lead candidate ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study in endometrial cancer.
- The near-term move reflected profit-taking and broader pressure on small-cap biotechnology names rather than a single company-specific announcement.
- Investor attention remains focused on the prespecified interim analysis of the ACR-368 serous endometrial cancer arms expected in the second half of 2026.
- As of June 30, 2026, Acrivon reported $90.0 million in cash, cash equivalents, and investments, with runway projected into the fourth quarter of 2027.
- For deeper analysis, explore Acrivon's Price Targets, Earnings, and Forecast pages.
- You can also track AI-driven trading strategies for this ticker by exploring Trending AI Robots.
Acrivon Therapeutics (ACRV) Company Overview and Market Position
Acrivon Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on discovering and developing precision oncology medicines. The company's approach is built around its proprietary Generative Phosphoproteomics platform, known as AP3 (Acrivon Predictive Precision Proteomics), which measures drug-regulated pathway activity inside intact cells to guide drug design and identify patients most likely to respond to treatment.
Acrivon's lead program, ACR-368 (also known as prexasertib), is a selective CHK1/CHK2 inhibitor being evaluated in a registrational-intent Phase 2b study for patients with recurrent, high-grade endometrial cancer. The FDA has granted Fast Track designation for ACR-368 in endometrial cancer, and the companion ACR-368 OncoSignature assay has received Breakthrough Device designation. The company's second clinical-stage asset, ACR-2316, is a WEE1/PKMYT1 inhibitor in Phase 1/2 development, and it is advancing ACR-6840, an internally discovered CDK11 inhibitor, toward an IND filing. Investors follow ACRV primarily for its clinical data catalysts and the potential of its AP3-enabled pipeline in areas of high unmet need.
Acrivon Therapeutics (ACRV) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ACRV declined from a closing level near $2.06 to approximately $1.74, a move of about -15.5%. The decline was gradual rather than a single-session shock, with the stock drifting lower through October and giving back much of the gains accumulated earlier in the period.
The broader quarterly picture is more nuanced. Early in the quarter, the stock traded near $1.56 before rallying sharply to a peak above $2.39 in mid-August, a gain of more than 50% from its starting point. Shares then consolidated in a range between roughly $1.95 and $2.20 through much of September before softening into October. Measured from the start of the quarter, the stock remains modestly higher, up roughly 11%, but it now sits about 27% below its August peak, reflecting a classic round-trip in a volatile clinical-stage biotech.
What Drove ACRV Stock Price in the Last 30 Days
The 30-day decline was not tied to a single company-specific announcement. Instead, the move appears to reflect a normalization of the strong rally that followed Acrivon's August business updates, combined with profit-taking and broader pressure on small-cap biotechnology equities. Clinical-stage biotech names without near-term revenue can experience outsized swings when sentiment toward the sector shifts, and ACRV's low trading volume amplifies day-to-day price movement.
Within the period, the stock staged a brief recovery in mid-to-late September before weakening again in October. The absence of fresh clinical data during the window left the stock to trade on technical factors and market sentiment. Investors continued to position ahead of the anticipated prespecified interim analysis for the ACR-368 Phase 2b serous endometrial cancer arms, a catalyst scheduled for the second half of 2026 that has kept the stock sensitive to shifting expectations about the timing and content of the readout.
What Drove ACRV Stock Performance Over the Last Quarter
Acrivon's quarterly move was shaped primarily by clinical and pipeline momentum. In early August, the company reported favorable safety and durable single-agent activity for ACR-2316, including heavily pretreated lung cancer patients remaining on treatment for over a year, and confirmed that ACR-2316 had advanced into the randomized dose-expansion stage of its Phase 1/2 study. In mid-August, alongside its second-quarter 2026 financial results, management reiterated that the prespecified interim analysis of the ACR-368 serous endometrial cancer arms remained on track for the second half of 2026 and that dosing continued across both arms in the U.S. and Europe.
These updates drove the stock's mid-August spike. As the initial enthusiasm faded and no major data readout arrived, shares gave back gains, a pattern common among development-stage oncology companies where valuation is heavily tied to binary clinical events. The quarterly trend therefore reflects a market that rewarded positive program progress but then de-risked into the data catalyst.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of its top-performing and most relevant AI-powered trading bots, drawn from a platform that offers hundreds of automated strategies across thousands of tickers. Rather than listing every available bot, this section highlights only those currently generating standout, verified performance and market relevance. The bots vary in strategy, holding timeframe, risk profile, and performance metrics, allowing traders to review each bot's track record, trade history, and settings before deciding whether it fits their own objectives. The page is designed to help users discover AI-driven tools aligned with their trading approach. To view the current lineup, explore the Trending AI Robots page.
ACRV Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst for ACRV is the prespecified simultaneous interim analysis of the ACR-368 Phase 2b study's all-comer serous endometrial cancer arms, expected in the second half of 2026. Management has also guided toward completing enrollment of the registrational-intent Arm 3 or Arm 4 by the fourth quarter of 2026, depending on the interim readout, with plans to initiate a Phase 3 confirmatory trial in the first half of 2027.
Beyond ACR-368, investors should monitor additional ACR-2316 dose-expansion data, the planned IND filing for the ACR-6840 CDK11 inhibitor, and any updates on AP3-driven discovery programs. Financial durability remains a key factor as well: with $90.0 million in cash reported as of June 30, 2026 and runway into the fourth quarter of 2027, capital-raising activity and spending discipline will influence sentiment. As with any clinical-stage biotech, the stock remains exposed to trial outcomes, regulatory decisions, and broader sector risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for ACRV turns negative, indicating new downward trend
ACRV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 30 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology